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After publication of this work [1], we noted that we in-
advertently failed to include the complete list of all co-
authors. In this erratum we rectify these mistakes. The
full list of authors and the updated Authors Contribu-
tions section are reported below. We apologize for any
inconvenience this oversight may have caused.
Corrected Authors’ List:
Anastasia S. Proskurina, Tatiana S. Gvozdeva, Ekaterina
A. Alyamkina, Evgenia V. Dolgova, Konstantin E.
Orishchenko, Valeriy P. Nikolin, Nelly A. Popova,
Sergey V. Sidorov, Elena R. Chernykh, Alexandr A.
Ostanin, Olga Y. Leplina, Victoria V. Dvornichenko,
Dmitriy M. Ponomarenko, Galina S. Soldatova, Nikolay A.
Varaksin, Tatiana G. Ryabicheva, Peter N. Uchakin,
Stanislav N. Zagrebelniy, Vladimir A. Rogachev, Sergey S.
Bogachev, and Mikhail A. Shurdov.
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